MD Anderson Obsidian get US FDA clearance to begin phase I study of novel TIL therapy OBX-115 to treat solid tumours

The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for an MD Anderson-sponsored phase I clinical study of OBX-115, Obsidian